These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32978365)

  • 1. The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma.
    Gavriatopoulou M; Βoultadaki A; Koutoulidis V; Ntanasis-Stathopoulos I; Bourgioti C; Malandrakis P; Fotiou D; Migkou M; Kanellias N; Eleutherakis-Papaiakovou E; Kastritis E; Terpos E; Dimopoulos MA; Moulopoulos LA
    Blood Cancer J; 2020 Sep; 10(9):93. PubMed ID: 32978365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM).
    Ippolito D; Besostri V; Bonaffini PA; Rossini F; Di Lelio A; Sironi S
    Eur J Radiol; 2013 Dec; 82(12):2322-7. PubMed ID: 24074647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].
    Bhutani M; Landgren O
    Radiologe; 2014 Jun; 54(6):572, 574-81. PubMed ID: 24927659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma.
    Gundesen MT; Asmussen JT; Haukås E; Schubert M; Abildgaard N; Schjesvold F; Lund T
    Eur J Haematol; 2022 May; 108(5):423-429. PubMed ID: 35113466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving diagnostic criteria for multiple myeloma.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2015; 2015():272-8. PubMed ID: 26637733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma.
    Jamet B; Bailly C; Carlier T; Touzeau C; Michaud AV; Bourgeois M; Moreau P; Bodet-Milin C; Kraeber-Bodere F
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
    Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
    Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implemented myeloma management with whole-body low-dose CT scan: a real life experience.
    Mangiacavalli S; Pezzatti S; Rossini F; Doni E; Cocito F; Bolis S; Corso A
    Leuk Lymphoma; 2016 Jul; 57(7):1539-45. PubMed ID: 26788613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Advances in the Management of Smoldering Myeloma.
    Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
    Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
    Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J
    Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
    Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
    JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
    Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.